UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

Hepatology international, 2021-02, Vol.15 (1), p.93-104

2021

Volltextzugriff (PDF)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

BMC cancer, 2010-06, Vol.10 (1), p.277-277, Article 277

2010

Volltextzugriff (PDF)

Is surgery always necessary in esophageal cancer?

Esophagus : official journal of the Japan Esophageal Society, 2011-03, Vol.8 (1), p.3-7

2011

Volltextzugriff (PDF)

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

Clinical gastroenterology and hepatology, 2018-06, Vol.16 (6), p.892-899.e2

2018

Volltextzugriff (PDF)

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

Digestive and liver disease, 2018-01, Vol.50 (1), p.15-19

2018

Volltextzugriff (PDF)

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

Journal of clinical oncology, 2021-10, Vol.39 (29), p.3242-3250

2021

Volltextzugriff (PDF)

Rectal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

Digestive and liver disease, 2017-04, Vol.49 (4), p.359-367

2017

Volltextzugriff (PDF)

Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?

Journal of thoracic disease, 2017-10, Vol.9 (10), p.3594-3597

2017

Volltextzugriff (PDF)

Patterns of care and outcomes in oesophageal cancer

Digestive and liver disease, 2018-11, Vol.50 (11), p.1238-1243

2018

Volltextzugriff (PDF)

Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma

Anti-cancer drugs, 2011-09, Vol.22 (8), p.741-748

2011

Volltextzugriff (PDF)

Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3550-3550

2017

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2007-09, Vol.25 (25), p.4026-4027

2007

Volltextzugriff (PDF)

Factors influencing inclusion in digestive cancer clinical trials: A population-based study

Digestive and liver disease, 2015-10, Vol.47 (10), p.891-896

2015

Volltextzugriff (PDF)

Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4019-4019

2017

Volltextzugriff (PDF)

FOLFIRI + bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 – FFCD 0802)

Digestive and liver disease, 2015-04, Vol.47 (4), p.271-272

2015

Volltextzugriff (PDF)

Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3532-3532

2016

Volltextzugriff (PDF)

Discontinuation of first-line chemotherapy (CT) after 6 weeks of CT in patients (pts) with metastatic squamous-cell esophageal cancer (MSEC): A randomized phase II trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4002-4002

2016

Volltextzugriff (PDF)

PRODIGE 34 – FFCD 1402 – ADAGE

Digestive and liver disease, 2016-02, Vol.48 (2), p.206-207

2016

Volltextzugriff (PDF)

Clinical results at 3 years of the ACCORD 12 randomized trial in rectal cancer

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.389-389

2012

Volltextzugriff (PDF)

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3541-3541

2015

Volltextzugriff (PDF)

Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland

Radiation oncology (London, England), 2015-05, Vol.10 (1), p.116-116, Article 116

2015

Volltextzugriff (PDF)

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3614-3614

2013

Volltextzugriff (PDF)

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

The lancet oncology, 2014-07, Vol.15 (8), p.862-873

2014

Volltextzugriff (PDF)

Predictors of disease control in patients treated with platinum-based chemotherapies for metastatic squamous-cell esophageal cancer: First results of the e-DIS trial

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.95-95

2014

Volltextzugriff (PDF)

Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3525-3525

2013

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(53)
magazinearticle
(1)

Sprache

Englisch
(41)
Französisch
(13)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

Is surgery always necessary in esophageal cancer?

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

Rectal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?

Patterns of care and outcomes in oesophageal cancer

Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma

Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients

In Reply

Factors influencing inclusion in digestive cancer clinical trials: A population-based study

Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial

FOLFIRI + bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 – FFCD 0802)

Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials

Discontinuation of first-line chemotherapy (CT) after 6 weeks of CT in patients (pts) with metastatic squamous-cell esophageal cancer (MSEC): A randomized phase II trial

PRODIGE 34 – FFCD 1402 – ADAGE

Clinical results at 3 years of the ACCORD 12 randomized trial in rectal cancer

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial

Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

Predictors of disease control in patients treated with platinum-based chemotherapies for metastatic squamous-cell esophageal cancer: First results of the e-DIS trial

Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC)

Aktive Filter

Suchergebnisse filtern